Research and Markets: EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l998cx/epicast_report) has announced the addition of GlobalData's new report "EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022" to their offering.

“EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022”

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults (Fernandes de Abreu et al., 2009). In 2012, the US had the highest number of prevalent and incident cases among the 10 markets, and will continue to comprise the largest portion of the market until 2022. Western countries in the analysis had a higher number of prevalent cases in 2012 than did Asian countries (India, China, and Japan); however, this was not true for incident cases. In 2012, China had more incident cases than all countries except the US, and India had a higher number of incident cases than Italy, Spain, and Japan. The prevalence and incidence of MS vary greatly by age, gender, and geographical location. Regional differences in MS prevalence and incidence could be due to several factors including diagnostic criteria used, availability of medical technology, genetic and environmental risk factors, frequency of comorbidities, and population age and gender structure.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Epidemiology

3.1 Risk Factors

3.1.1 Family members of MS patients have a 1%-5% risk of developing MS

3.1.2 Women are twice as likely to develop MS, but men have a worse prognosis

3.1.3 Caucasians have a higher risk of MS than any other race/ethnicity

3.1.4 Protective effect of vitamin D on MS may relate to latitude and month of birth

3.1.5 Timing of environmental exposures affects MS risk

3.1.6 Exposure to smoking may increase MS risk and worsen prognosis

3.2 Comorbidities

3.2.1 Autoimmune diseases may be comorbidities of MS

3.2.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates

3.3 Global Trends

3.4 Forecast Methodology

3.5 Epidemiology Forecast of Multiple Sclerosis

3.5.1 Total Prevalent Cases of Multiple Sclerosis

3.5.2 Age-Specific Prevalent Cases of Multiple Sclerosis

3.5.3 Gender-Specific Prevalent Cases of Multiple Sclerosis

3.5.4 Total Incident Cases of Multiple Sclerosis

3.5.5 Age-Specific Incident Cases of Multiple Sclerosis

3.5.6 Gender-Specific Incident Cases of Multiple Sclerosis

3.5.7 Multiple Sclerosis Subtypes

3.6 Discussion

4 Appendix

For more information visit http://www.researchandmarkets.com/research/l998cx/epicast_report

Source: GlobalDatap